• Explore /
  • Poster
  • / Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.

Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.

Abstract Poster

Authors

null

Tara Elisabeth Seery

Chan Soon Shiong Institute for Medicine, El Segundo, CA

Tara Elisabeth Seery , Chaitali Singh Nangia , Heidi Ann McKean , Paul Bhar , Leonard S. Sender , Sandeep K. Reddy , Patrick Soon-Shiong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT04390399

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4147)

DOI

10.1200/JCO.2022.40.16_suppl.4147

Abstract #

4147

Poster Bd #

132

Abstract Disclosures

Similar Posters

First Author: Muhammad Shaalan Beg

Poster

2015 Gastrointestinal Cancers Symposium

Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.

Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.

First Author: Sunil R. Hingorani

First Author: John Ebben

First Author: Inna Markovna Chen